UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
August 26, 2004
Date of Report (date of Earliest Event Reported)
ISOLAGEN, INC.
(Exact Name of Registrant as Specified in its Charter)
|
DELAWARE |
|
001-31564 |
|
87-0458888 |
|
(State or Other Jurisdiction of |
|
(Commission File No.) |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
|
|
2500 Wilcrest, 5th Floor, Houston, Texas 77042 |
||||
|
(Address of principal executive offices and zip code) |
||||
|
|
||||
|
(713) 780-4754 |
||||
|
(Registrant’s telephone number, including area code) |
||||
|
|
||||
|
Not applicable |
||||
|
(Former name or former address, if changed from last report) |
||||
On August 26, 2004, the Company issued a press release announcing the Company has been granted EU patent EP0845963 entitled “The Use of Autologous Dermal Fibroblasts for the Repair of Skin and Soft Tissue Defects” covering the Company’s proprietary Isolagen Process in 17 European countries. The reader is advised to read the press release in its entirety.
[THE SIGNATURE PAGE FOLLOWS.]
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ISOLAGEN, INC. |
||
|
|
|
|
|
|
|
|
|
|
|
Date: August 26, 2004 |
By: |
/s/ Jeffrey W. Tomz |
|
|
|
|
Chief Financial Officer |
|
2